ADAM metallopeptidase with thrombospondin type 1 motif 19
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from ADAMTS19)
 | This article is a stub. |
ADAMTS19 or ADAM metallopeptidase with thrombospondin type 1 motif 19 or ADAM metallopeptidase domain 19 or A Disintegrin-Like And Metalloprotease (Reprolysin Type) With Thrombospondin Type 1 Motif, 19 is a protein-encoding gene.[1]
Function[edit | edit source]
ADAMTS19 is associated with discrete subaortic stenosis and subvalvular aortic stenosis.[1]
ME/CFS[edit | edit source]
The first publication from the long term ME/CFS Gene Study, which used the Fukuda criteria for chronic fatigue syndrome only, looked for the SNPs that were more common in CFS patients than in healthy people, and which were most likely to be harmful. ADAMTS19 was one of the top ten genes most likely to be harmful thatmore common in CFS patients, occurring in over 70% of patients.[2]
Notable studies[edit | edit source]
- 2019, Genetic Predisposition for Immune System, Hormone, and Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study[2] (Full text)
See also[edit | edit source]
Learn more[edit | edit source]
- ADAMTS19 Gene - Gene card
References[edit | edit source]
- ↑ 1.0 1.1 "ADAMTS19 Gene - ADAM metallopeptidase with thrombospondin type 1 motif 19 - Gene card". Gene cards. Retrieved May 25, 2022.
- ↑ 2.0 2.1 Nathanson, Lubov; Craddock, Travis J.A.; Klimas, Nancy G.; Gemayel, Kristina; Del Alamo, Ana; Hilton, Kelly; Jaundoo, Rajeev; Perez, Melanie (2019). "Genetic Predisposition for Immune System, Hormone, and Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study". Frontiers in Pediatrics. 7: 206. doi:10.3389/fped.2019.00206. ISSN 2296-2360.
